Article
Document
Academic Article
Information Content Entity
Continuant
Continuant
Journal Article
Entity
Entity
Generically Dependent Continuant
2025-05-11T20:09:28
RDF description of Benefits of dexmedetomidine in management of post-ECT agitation - http://repository.healthpartners.com/individual/document-rn7386
10.1097/yct.0000000000000393
Drugs and Drug Therapy
3
33
13605
public
Benefits of dexmedetomidine in management of post-ECT agitation
<p>Electroconvulsive therapy (ECT) is an intervention for patients with a variety of psychiatric conditions. Occasionally, people exhibit dangerous degrees of agitation after this treatment, and some do not respond well to conventional pharmacotherapies. Dexmedetomidine is a central alpha-2 agonist that can induce significantly calmative effects in persons with post-ECT agitation. The indication for it is in calming individuals with acute and/or recurrent posttreatment agitation. Dexmedetomidine is safe and effective when infused just before, or postictally, at ECT sessions.<p>
2022-02-21T22:48:57.408-06:00
Journal of ECT
Adverse Effects
Mental Disorders
21790
document-rn7386